Novartis has announced plans to acquire Tourmaline Bio for $48 per share, valuing the New York-based biotech at $1.4 billion, strengthening its cardiovascular disease portfolio with a Phase III ready therapy.
𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀:
👉 Pacibekitug, Tourmaline’s lead asset, targets systemic inflammation in atherosclerotic cardiovascular disease (ASCVD)
👉 Phase III–ready therapy complements Novartis’s existing cardiovascular portfolio
👉 Unanimously approved by both boards; Novartis will launch a tender offer to acquire all outstanding shares
👉 Deal expected to close in Q4 2025, after which Tourmaline will become an indirect, wholly owned subsidiary
A major move in the cardiovascular space – Novartis wants to be the leader.
Congrats to the teams at Novartis and Tourmaline Bio!
Source : Spencer Knight – linkedin
